Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Gisela Mautner"'
Autor:
Koba Kiknavelidze, PhD, Mikheil Shavdia, PhD, Nana Chikhladze, PhD, Lia Abshilava, PhD, Marinella Messina, PhD, Gisela Mautner, MD, PhD, Graham Kelly, PhD
Publikováno v:
Current Therapeutic Research, Vol 94, Iss , Pp 100631- (2021)
ABSTRACT: Background: Although oral and intravenous forms of idronoxil have been well tolerated, the safety of NOX66, with idronoxil formulated as a rectal suppository, is not known. This Phase Ia/b clinical study (protocol No. NOX66-001A), known as
Externí odkaz:
https://doaj.org/article/24400cffabfb40e2a1d6a3e7720452a7
Autor:
Koba Kiknavelidze, Marinella Messina, Lia Abshilava, Gisela Mautner, Nana Chikhladze, Graham Kelly, Mikheil Shavdia
Publikováno v:
Current Therapeutic Research, Clinical and Experimental
Current Therapeutic Research, Vol 94, Iss, Pp 100631-(2021)
Current Therapeutic Research, Vol 94, Iss, Pp 100631-(2021)
Highlights • NOX66 contains idronoxil, formulated as a rectal suppository. • CEP-1 is the first study to assess NOX66 in patients with refractory solid tumors. • NOX66 was well tolerated at 400/800 mg as monotherapy and combined with carboplati
Autor:
Gisela Mautner, Zaza Mezvrishvili, Marinella Messina, Paul de Souza, Anne Capp, Nana Chikhladze
Publikováno v:
Journal of Clinical Oncology. 38:5533-5533
5533 Background: NOX66 is a new formulation of the small molecule, idronoxil. The primary mechanism of action of idronoxil stems from its binding to the transmembrane enzyme ENOX2 expressed on cancer cells, resulting in reduced S1P and increased cera
Autor:
MAUTNER, GISELA1
Publikováno v:
Australasian Biotechnology. Oct2023, Vol. 33 Issue 2, p22-24. 3p.
Publikováno v:
Australasian Biotechnology. Apr2024, Vol. 34 Issue 1, p40-42. 3p.
Publikováno v:
Asia Pacific Journal of Clinical Oncology. Nov2019 Supplement S9, Vol. 15, p27-54. 28p.
Autor:
Noxopharm
Publikováno v:
Business Wire (English). 02/25/2020.
Autor:
Noxopharm
Publikováno v:
Business Wire (English). 02/14/2020.